The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial.
M. M. Reinholz
No relevant relationships to disclose
A. C. Dueck
No relevant relationships to disclose
B. Chen
No relevant relationships to disclose
X. Geiger
No relevant relationships to disclose
A. E. McCullough
Consultant or Advisory Role - Genentech
R. B. Jenkins
No relevant relationships to disclose
W. L. Lingle
No relevant relationships to disclose
C. Andorfer
No relevant relationships to disclose
N. E. Davidson
No relevant relationships to disclose
S. Martino
No relevant relationships to disclose
P. A. Kaufman
Consultant or Advisory Role - Genentech
Research Funding - CALGB
L. A. Kutteh
No relevant relationships to disclose
G. W. Sledge
No relevant relationships to disclose
L. Harris
No relevant relationships to disclose
J. Gralow
Research Funding - Amgen; Genentech; Novartis; Roche
E. A. Perez
Research Funding - Genentech; GlaxoSmithKline